Josephine van Dongen

4 Rotavirus vaccine effectiveness 103 Table 3. Primary, secondary and post-hoc outcomes Outcome Estimate 95% CI Vaccine effectiveness Effectiveness against severe rotavirus AGE ≥ 14 days after HRV administration * HR 0.70 0.35;1.40 30% Impact on rotavirus AGE hospitalization in post-implementation period RR 0.76 0.10;6.37 24% Effectiveness against rotavirus AGE of any severity among HRV vaccinated infants # IRR 1.02 0.69;1.50 -2% Effectiveness against severe rotavirus AGE ≥ 14 days after full course HRV * HR 0.62 0.31;1.21 38% Effectiveness against severe all-cause AGE ≥ 14 days after HRV administration * HR 0.81 0.55;1.19 19% Impact on all-cause AGE hospitalization in post-implementation period RR 1.05 0.68;1.65 -5% Effectiveness against all-cause AGE of any severity among HRV vaccinated infants # IRR 0.87 0.76;1.01 13% *Adjusted for daycare attendance and rotavirus epidemic intensity. #Adjusted for daycare attendance and parental educational level. Abbreviations: HR = hazard rate, RR = relative risk, IRR = incidence rate ratio and, CI = confidence interval. All-cause AGE The post-hoc analyses on severe all-cause AGE resulted in a VE estimate of 19% (95%CI -19;45%) for vaccinated versus unvaccinated infants in the ATP cohor t. And HRV impact on all-cause AGE hospitalizations in the post- versus pre-implementation cohor t of -5%, see table 3. The incidence rate of all-cause AGE of any severity in the pre- and post-implementation ATP cohor ts was 733.9 (95%CI 670.7;800.7) and 660.3 (95%CI 608.7;715.4) per 1000 person-years, respectively. Results of subgroup analyses for all-cause AGE are presented in appendix. The applied Bayesian analysis yielded a posterior probability of 0·049 for estimating a VE more than 60%, figure 3 .